Steve Schoenfeld

508 total citations · 1 hit paper
15 papers, 363 citations indexed

About

Steve Schoenfeld is a scholar working on Genetics, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Steve Schoenfeld has authored 15 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Oncology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Steve Schoenfeld's work include Bone health and treatments (4 papers), Diabetes and associated disorders (3 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Steve Schoenfeld is often cited by papers focused on Bone health and treatments (4 papers), Diabetes and associated disorders (3 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Steve Schoenfeld collaborates with scholars based in United States, Canada and Germany. Steve Schoenfeld's co-authors include Melinda Gooderham, Misti Linaberry, Shinichi Imafuku, Bruce Strober, Diamant Thaçi, April W. Armstrong, Jacek C. Szepietowski, John Throup, Akimichi Morita and Richard B. Warren and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Diabetes.

In The Last Decade

Steve Schoenfeld

14 papers receiving 354 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by Steve Schoenfeld

Since Specialization

Citations

This map shows the geographic impact of Steve Schoenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Schoenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Schoenfeld more than expected).

Fields of papers citing papers by Steve Schoenfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Schoenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Schoenfeld. The network helps show where Steve Schoenfeld may publish in the future.

Co-authorship network of co-authors of Steve Schoenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Schoenfeld. A scholar is included among the top collaborators of Steve Schoenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Schoenfeld. Steve Schoenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION 2023 ·Neuro-Oncology ·Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Jose Carlos Méndez, Liam Welsh, Warren Mason, Andreas F. Hottinger, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, Steve Schoenfeld, Dongdong Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy	0
2	Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary 2023 ·Immunotherapy ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	2
3	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	219
4	A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE LIVER-SELECTIVE TR-BETA AGONIST VK2809 (MB07811) IN HYPERCHOLESTEROLEMIC SUBJECTS 2016 ·Journal of the American College of Cardiology ·(unknown), Rochelle M. Hanley, Steve Schoenfeld	11
5	Cost-Related Non-Adherence and Its Relationship to Medication Non-Adherence Among Adult Heart Transplant Recipients in Ten Countries - A Multicenter Cross-Sectional Study 2015 ·The Journal of Heart and Lung Transplantation ·Steve Schoenfeld, Lut Berben, Sabina De Geest	2
6	First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. 2010 ·Journal of Clinical Oncology ·Lee S. Rosen, David S. Mendelson, Richard B. Cohen, Michael Gordon, (unknown), (unknown), (unknown), (unknown), Steve Schoenfeld, Ashwin Gollerkeri	18
7	First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors 2008 ·Journal of Clinical Oncology ·David S. Mendelson, Melissa Dinolfo, Richard B. Cohen, Lee S. Rosen, Michael Gordon, (unknown), (unknown), Steve Schoenfeld	5
8	Are Needle-Free Injections a Useful Alternative for Growth Hormone Therapy in Children? Safety and Pharmacokinetics of Growth Hormone Delivered by a New Needle-Free Injection Device Compared to a Fine Gauge Needle 2003 ·Journal of Pediatric Endocrinology and Metabolism ·Helmuth G. Dörr, Siegfried Zabransky, (unknown), B. Otten, C. J. Partsch, Lars Nyman, (unknown), (unknown), Alastair Wilson, (unknown), (unknown), Peter Schuld, Steve Schoenfeld	33
9	Cyclical etidronate: Efficacy and safety over seven years 1996 ·Osteoporosis International ·C. H. Chesnut, (unknown), P. D. Miller, Anna Licata, (unknown), Richard D. Wasnich, (unknown), (unknown), H K Genant, Steve Schoenfeld, David Valent	1
10	Seven years of cyclical etidronate: Continued improvement in spine bmd and progressive decline in vertebral fracture incidence 1995 ·Bone ·(unknown), Paul D. Miller, Anna Licata, Richard D. Jackson, R.D. Wasnich, (unknown), S. T. Harris, Harry K. Genant, Steve Schoenfeld, David Valent, (unknown)	5
11	PHARMACOKINETICS OF PAMIDRONATE DISODIUM IN CANCER PATIENTS AFTER A SINGLE INTRAVENOUS INFUSION OF 30-, 60− OR 90-mg DOSE OVER 4 OR 24 HOURS 1994 ·American Journal of Therapeutics ·Wing K. Cheung, Lane J. Brunner, Steve Schoenfeld, Robert Knight, John J. Seaman, Alan Brox, Gerald Batist, V. A. John, Keith K. H. Chan	6
12	A SINGLE-DOSE BIOAVAILABILITY STUDY OF PAMIDRONATE DISODIUM AFTER ORAL ADMINISTRATION AS ENCAPSULATED ENTERIC-COATED PELLETS, ENTERIC-COATED TABLETS, AND A SOLUTION TO PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS 1994 ·American Journal of Therapeutics ·Wing K. Cheung, (unknown), Steve Schoenfeld, Robert Knight, John J. Seaman, (unknown), V. A. John, (unknown), Keith K. H. Chan	2
13	Increased specificity and sensitivity of insulin antibody measurements in autoimmune thyroid disease and type I diabetes 1992 ·Journal of Immunological Methods ·Matthew Hegewald, Steve Schoenfeld, D. K. McCulloch, Carla J. Greenbaum, Leslie J. Klaff, Jerry P. Palmer	16
14	Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study 1990 ·Diabetes ·D. K. McCulloch, (unknown), (unknown), Steve Schoenfeld, Carla J. Greenbaum, (unknown), (unknown), Gerald T. Nepom, (unknown), (unknown)	25
15	Systematic variation and differences in insulin-autoantibody measurements 1989 ·Diabetes ·(unknown), Steve Schoenfeld, (unknown), (unknown), Ezio Bonifacio, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact